Possibilities of using calcium lactate in combination with a prebiotic complex in the therapy of chronic dermatoses
- Authors: Katkova K.V1, Ramazanova T.R1, Belenkova A.A1, Denisova E.V1,2, Korsunskaya I.M2, Kolodkin A.M3
-
Affiliations:
- Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
- Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Moscow Healthcare Department
- Scientific Society «Mikrobiota»
- Issue: Vol 33, No 5 (2022)
- Pages: 78-82
- Section: From Practice
- URL: https://journals.eco-vector.com/0236-3054/article/view/114626
- DOI: https://doi.org/10.29296/25877305-2022-05-16
- ID: 114626
Cite item
Open Access
Access granted
Abstract
There is now a lot of scientific evidence suggesting that the gut microbiome affects many human body organs, including the skin. In this connection, intensive study is being given to the possibility of including drugs that favors normalization of the composition of intestinal microflora in order to improve the skin process. These agents may include metabiotics and prebiotic complexes that contain substances that activate the growth of normal flora. There is evidence of a fairly common occurrence of dysbiosis and gastrointestinal disorders in atopic dermatitis (AD) and psoriasis. In this regard, the authors observed patients with AD and psoriasis who received combination therapy including calcium lactate and a prebiotic complex. The severity of symptoms was reduced just on days 3-5 days; whereas there was a significant clinical effect by day 14 of treatment. However, the mechanism of action of prebiotics on the course of psoriasis and AD requires further study.
Keywords
Full Text
About the authors
K. V Katkova
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Author for correspondence.
Email: marykor@bk.ru
T. R Ramazanova
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
A. A Belenkova
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences
Email: marykor@bk.ru
E. V Denisova
Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences; Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Moscow Healthcare Department
Email: marykor@bk.ru
Candidate of Medical Sciences, Moscow Healthcare Department
I. M Korsunskaya
Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Moscow Healthcare Department
Email: marykor@bk.ru
Professor
A. M Kolodkin
Scientific Society «Mikrobiota»
Email: marykor@bk.ru
References
- He Y., Wu W., Zheng H.M. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018; 24: 1532-5. DOI: 10.1038/ s41591-018-0164-x
- Polkowska-Pruszynska B., Gerkowicz A., Krasowska D. The gut microbiome alterations in allergic and inflammatory skin diseases-an update. J Eur Acad Derm Venereol. 2020; 34: 455-64. doi: 10.1111/jdv.15951
- Yoo J.Y., Groer M., Dutra S.V.O. et al. Gut Microbiota and Immune System Interactions. Microorganisms. 2020; 8: 1587. doi: 10.3390/microorganisms8101587
- Ramirez-Bosca A., Navarro-Lopez V., Martinez-Andres A. et al. Identification of Bacterial DNA in the Peripheral Blood of Patients with Active Psoriasis. JAMA Dermatol. 2015; 151: 670-1. doi: 10.1001/jamadermatol.2014.5585
- Ning L., Lifang P., Huixin H. Prediction Correction Topic Evolution Research for Metabolic Pathways of the Gut Microbiota. Front Mol Biosci. 2020; 7 :600720. doi: 10.3389/fmolb.2020.600720
- Johnson C.C., Ownby D.R. The infant gut bacterial microbiota and risk of pediatric asthma and allergic diseases. Transl Res. 2017; 179: 60-70. doi: 10.1016/j.trsl.2016.06.010
- Navarro-Lopez V., Ramirez-Bosca A., Ramon-Vidal D. et al. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2018; 154: 37-43. doi: 10.1001/jamadermatol.2017.3647
- Climent E., Martinez-Blanch J.F., Llobregat L. et al. Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial. Microorganisms. 2021; 9: 854. doi: 10.3390/microorganisms9040854
- Джорджиева О.В., Тогоева Л.Ш., Мельниченко О.О. и др. Изучение микробиоценоза кожи и кишечника у больных атопическим дерматитом. Эффективная фармакотерапия. 2012; 11:32-5.
- Джорджиева О.В., Тогоева Л.Ш., Диковицкая И.Г. и др. Лактофильтрум в комплексной терапии экземы. Эффективная фармакотерапия. 2011; 11: 28-30.
- Olejniczak-Staruch I., Ciążyńska M., Sobolewska-Sztychny D. et al. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2021; 22 (8): 3998. doi: 10.3390/ijms22083998
- Fry L., Baker B.S., Powles A.V. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol. 2013; 169: 47-52. doi: 10.1111/bjd.12322
- Fry L., Baker B.S., Powles A.V. et al. Psoriasis is not an autoimmune disease? Exp Dermatol. 2015; 24: 241-4. doi: 10.1111/exd.12572
- Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014; 157: 121-41. doi: 10.1016/j.cell.2014.03.011
- Valdimarsson H., Baker B.S., Jonsdottir I. et al. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today. 1995; 16: 145-9. doi: 10.1016/0167-5699(95)80132-4
- Leung D.Y., Travers J.B., Giorno R. et al. Evidence for a streptococcal superantigendriven process in acute guttate psoriasis. J Clin Invest. 1995; 96: 2106-12. doi: 10.1172/JCI118263
- Scher J.U., Ubeda C., Artacho A. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015; 67: 128-39. doi: 10.1002/art.38892
- Alesa D.I., Alshamrani H.M., Alzahrani Y.A. et al. The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics. J Family Med Prim Care. 2019; 8: 3496-503. doi: 10.4103/jfmpc.jfmpc_709_19
- Fry L., Baker B.S. Triggering psoriasis: The role of infections and medications. Clin Dermatol. 2007; 25: 606-15. doi: 10.1016/j.clindermatol.2007.08.015
- Eppinga H., Sperna Weiland C.J. et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016; 10: 1067-75. doi: 10.1093/ecco-jcc/jjw070
- Fu Y., Lee C.H., Chi C.C. Association of psoriasis with inflammatory bowel disease: A systematic review and meta-analysis. JAMA Dermatol. 2018; 154: 1417-23. DOI: 10.1001/ jamadermatol.2018.3631
- Ely P.H. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. Clin Dermatol. 2018; 36: 376-89. DOI: 10.1016/j. clindermatol.2018.03.011
- Groeger D., O'Mahony L., Murphy E.F. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013; 4: 325-39. DOI: 10.4161/ gmic.25487
- Suarez-Farinas M., Li K., Fuentes-Duculan J. et al. Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012; 132: 2552-64. doi: 10.1038/jid.2012.184
- Vandeputte D., Falony G., Vieira-Silva S. et al. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut. 2017; 66 (11): 1968-74. DOI:10.1136/ gutjnl-2016-313271
- Morita N., Umemoto E., Fujita S. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature. 2019; 566 (7742): 110-4. doi: 10.1038/s41586-019-0884-1
- Чичерин И.Ю., Погорельский И.П., Колодкин А.М. и др. Роль колонизационной резистентности слизистой оболочки кишечника в развитии инфекций бактериальной природы желудочно-кишечного тракта. Инфекционные болезни. 2019; 17 (3): 55-68. doi: 10.20953/1729-9225-2019-3-55-68
- Минушкин О.Н., Масловский Л.В., Ардатская М.Д. и др. Клинико-метаболические эффекты терапии метапребиотиками некоторых функциональных заболеваний кишечника. Экспериментальная и клиническая гастроэнтерология. 2021; 10: 100-8. doi: 10.31146/1682-8658-ecg-194-10-100-10
Supplementary files
